Find Clinical Trial

A Phase 1, Multicenter, Randomized, Controlled, Open-label, Perioperative Study of AG-120 and AG-881 in Subjects with Recurrent, Non-enhancing, IDH1 Mutant, Low-grade Glioma


← Back
Study Phase

Phase 1

Therapeutic Area

Cancers

IndicationGlioma
SponsorInstitut de Recherches Internationales Servier
Active substance/
Medical device

AG-120, AG881

Active Substance CodeAG-120, AG881
Protocol CodeAG120-881-C-001
EudraCT Code2018-001199-39
NCT CodeNCT03343197


Documents and links

Results are not yet available.




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2021 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility